Cargando…

A single-institution retrospective analysis of pathologically determined malignant transformation in IDH mutant glioma patients

BACKGROUND: Lower-grade IDH mutant glioma patients frequently undergo malignant transformation (MT), with apparent worse prognosis. Many studies examine MT in mixed IDH status cohorts and define MT using imaging, not histopathology. Our study examines the timing, predictors, and prognostic implicati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Vicki, Wetzel, Ethan A, Eldred, Blaine S C, Zapanta Rinonos, Serendipity, Prins, Terry J, Khanlou, Negar, Liau, Linda M, Chong, Robert, Nghiemphu, Phioanh L, Cloughesy, Timothy F, Ellingson, Benjamin M, Lai, Albert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Clinical Investigations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10162112/ https://www.ncbi.nlm.nih.gov/pubmed/37152809 http://dx.doi.org/10.1093/noajnl/vdad036

Ejemplares similares

Retrospective examination of pseudoprogression in IDH mutant gliomas
por: Wetzel, Ethan A, et al.
Publicado: (2023)

Prognostic value of O(6)-methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomas
por: Lam, Keng, et al.
Publicado: (2022)

Early volumetric, perfusion, and diffusion MRI changes after mutant isocitrate dehydrogenase (IDH) inhibitor treatment in IDH1-mutant gliomas
por: Cho, Nicholas S, et al.
Publicado: (2022)

BIMG-11. PHARMACODYNAMIC EVALUATION OF IDH AND EGFR INHIBITION IN HUMAN GLIOMAS USING MOLECULAR MRI
por: Ellingson, Benjamin, et al.
Publicado: (2021)

Differentiating IDH status in human gliomas using machine learning and multiparametric MR/PET
por: Tatekawa, Hiroyuki, et al.
Publicado: (2021)

Human IDH mutant 1p/19q co-deleted gliomas have low tumor acidity as evidenced by molecular MRI and PET: a retrospective study
por: Yao, Jingwen, et al.
Publicado: (2020)

Paradoxical Association Between Relative Cerebral Blood Volume Dynamics Following Chemoradiation and Increased Progression-Free Survival in Newly Diagnosed IDH Wild-Type MGMT Promoter Methylated Glioblastoma With Measurable Disease
por: Goldman, Jodi, et al.
Publicado: (2022)

Validation of vessel size imaging (VSI) in high-grade human gliomas using magnetic resonance imaging, image-guided biopsies, and quantitative immunohistochemistry
por: Chakhoyan, Ararat, et al.
Publicado: (2019)

Change in volumetric tumor growth rate after cytotoxic therapy is predictive of overall survival in recurrent glioblastoma
por: Oshima, Sonoko, et al.
Publicado: (2023)

The Future Glioblastoma Clinical Trials Landscape: Early Phase 0, Window of Opportunity, and Adaptive Phase I–III Studies
por: Cho, Nicholas S., et al.
Publicado: (2023)

A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas
por: Nghiemphu, Phioanh Leia, et al.
Publicado: (2012)

Patterns of long-term survivorship following bevacizumab treatment for recurrent glioma: a case series
por: Liu, Liang Yen, et al.
Publicado: (2019)

Diagnostic and Prognostic Value of pH- and Oxygen-Sensitive Magnetic Resonance Imaging in Glioma: A Retrospective Study
por: Yao, Jingwen, et al.
Publicado: (2022)

Daily functioning in glioma survivors: associations with cognitive function, psychological factors and quality of life
por: Van Dyk, Kathleen, et al.
Publicado: (2022)

Insulator dysfunction and oncogene activation in IDH mutant gliomas
por: Flavahan, William A., et al.
Publicado: (2015)

Association between lesion location and language function in adult glioma using voxel-based lesion-symptom mapping
por: Banerjee, Pia, et al.
Publicado: (2015)

Visualization of tumor heterogeneity and prediction of isocitrate dehydrogenase mutation status for human gliomas using multiparametric physiologic and metabolic MRI
por: Hagiwara, Akifumi, et al.
Publicado: (2022)

Improving B(0) Correction for pH-Weighted Amine Proton Chemical Exchange Saturation Transfer (CEST) Imaging by Use of k-Means Clustering and Lorentzian Estimation
por: Yao, Jingwen, et al.
Publicado: (2018)

Therapies for IDH-Mutant Gliomas
por: Alshiekh Nasany, Ruham, et al.
Publicado: (2023)

Characterization of cognitive function in survivors of diffuse gliomas using resting-state functional MRI (rs-fMRI)
por: Wang, Chencai, et al.
Publicado: (2021)

Characterization of Cognitive Function in Survivors of Diffuse Gliomas Using Morphometric Correlation Networks
por: Wang, Chencai, et al.
Publicado: (2022)

Relapse patterns and radiation dose exposure in IDH wild-type glioblastoma at first radiographic recurrence following chemoradiation
por: Shidoh, Satoka, et al.
Publicado: (2022)

DDRE-12. HETEROGENOUS RESPONSE OF IDH-MUTANT AND IDH-WT GLIOMA TO NAMPT INHIBITION
por: Rahman, Masum, et al.
Publicado: (2021)

Targeted next-generation sequencing of 565 neuro-oncology patients at UCLA: A single-institution experience
por: Ji, Matthew S, et al.
Publicado: (2020)

Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial
por: Mellinghoff, Ingo K., et al.
Publicado: (2023)

Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers
por: Unruh, Dusten, et al.
Publicado: (2019)

Postoperative risk of IDH-mutant glioma–associated seizures and their potential management with IDH-mutant inhibitors
por: Drumm, Michael R., et al.
Publicado: (2023)

Stalled oligodendrocyte differentiation in IDH-mutant gliomas
por: Wei, Yanfei, et al.
Publicado: (2023)

Updates on the WHO diagnosis of IDH-mutant glioma
por: Reuss, David.E.
Publicado: (2023)

Multi-nuclear sodium, diffusion, and perfusion MRI in human gliomas
por: Cho, Nicholas S., et al.
Publicado: (2023)

Genomic profiles of IDH-mutant gliomas: MYCN-amplified IDH-mutant astrocytoma had the worst prognosis
por: Lee, Kwanghoon, et al.
Publicado: (2023)

Metabolic Reprogramming in Mutant IDH1 Glioma Cells
por: Izquierdo-Garcia, Jose L., et al.
Publicado: (2015)

Mutant IDH1 Promotes Glioma Formation In Vivo
por: Philip, Beatrice, et al.
Publicado: (2018)

Epigenetic Reprogramming for Targeting IDH-Mutant Malignant Gliomas
por: Park, Jong-Whi, et al.
Publicado: (2019)

Malignant Progression of an IDH Mutant Brainstem Glioma in Adult
por: SANO, Kenshi, et al.
Publicado: (2021)

Proteome-based insights for IDH-mutant glioma classification
por: Leu, Severina, et al.
Publicado: (2023)

Mutant IDH in Gliomas: Role in Cancer and Treatment Options
por: Solomou, Georgios, et al.
Publicado: (2023)

“Aerobic glycolytic imaging” of human gliomas using combined pH-, oxygen-, and perfusion-weighted magnetic resonance imaging
por: Hagiwara, Akifumi, et al.
Publicado: (2021)

Multi-Parametric Radiomic Model to Predict 1p/19q Co-Deletion in Patients with IDH-1 Mutant Glioma: Added Value to the T2-FLAIR Mismatch Sign
por: Kihira, Shingo, et al.
Publicado: (2023)

Decorin expression is associated with predictive diffusion MR phenotypes of anti-VEGF efficacy in glioblastoma
por: Patel, Kunal S., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8iqsrc4re36qd5q7f05bqjdjs0